Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 2, 2003, Pages 178-185

  Hedman, Mia ^a   Neuvonen, Pertti J ^a   Neuvonen, Mikko ^a   Antikainen, Marjatta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL TOXICITY; HEADACHE; HETEROZYGOSITY; HUMAN; MYALGIA; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN MANIFESTATION; SLEEP DISORDER;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CHILD; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PRAVASTATIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRIGLYCERIDES;

EID: 0041625769     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00153-X     Document Type: Article

References (29)

1. Aalto-Setälä K, Helve E, Kovanen PT, Kontula K. Finnish type of low density lipoprotein receptor mutation (FH-Helsinki) deletes exons encoding the carboxy terminal part of the receptor and creates an internalization-defective phenotype. J Clin Invest 1989;84:499-505.
2. Vuorio AF, Aalto-Setälä K, Koivisto UM, Turtola H, Nissen H, Kovanen PT, et al. Familial hypercholesterolemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Ann Med 2001;33:410-21.
3. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:3332-7.
4. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996;16:984-91.
5. Tonstad S, Joakimsen O, Stensland-Bugge E, Ose L, Bonaa KH, Leren TP. Carotid intima-media thickness and plaque in patients with familial hypercholesterolemia mutations and control subjects. Eur J Clin Invest 1998;28:971-9.
6. Knipscheer HC, Boelen CCA, Kastelein JJP, Van Diermen DE, Groenemeijer BE, Van den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996;39:867-71.
7. McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hypercholesterolemia. Pediatr Res 2002;51:715-21.
8. Penson MG, Fricker FJ, Thompson JR, Harker K, Williams BJ, Kahler DA, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001;20:611-8.
9. Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlois S, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics 1996;97:619-28.
10. Kwiterovich PO Jr. Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin. Nutr Metab Cardiovasc Dis 2001;11:30-4.
11. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-7.
12. Pan HY, Triscari J, De Vault AR, Smith SA, Wang-Iverson D, Swanson BN, et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991;31:665-70.
13. Quion JA, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994;27:94-103.
14. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990;29:239-43.
15. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8.
16. Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 2002;78:43-54.
17. Evertt DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991;19:740-8.
18. Hatanaka T. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 2000;39:397-412.
19. Pan HY, De Vault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990;30:1128-35.
20. Neuvonen PJ, Kantola T, Kivistiö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
21. Cuthbert JA, East CA, Bilheimer DW, Lipsky PE. Detection of familial hypercholesterolemia by assaying functional low-density-lipoprotein receptors on lymphocytes. N Engl J Med 1986;314:879-83.
22. Mulvana D, Jemal M, Pulver SC. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal 2000;23:851-66.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
24. Gordon DJ, Probsfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
25. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
26. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
27. Pan HY, De Vault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990;48:201-7.
28. Triscari J, O'Donnell D, Zinny M, Pan HY. Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 1995;35:142-4.
29. Jones PH, Farmer JA, Cressman DO, McKenney JM, Wright JT, Proctor JD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 1991;14:146-51.